CytoTronics develops semiconductor-to-live-cell interfaces called Pixel that provide multi-modal, single-cell resolution monitoring of viability, morphology, electrophysiology and more. The company launched early access programs for Pixel Primo and Pixel Octo, with Pixel Octo aimed at improving scalability for high-throughput discovery applications. Pixel has received a 2024 SLA New Product Award and an R&D 100 award. CytoTronics plans to expand commercial and field teams, scale manufacturing and production, and is preparing for first product shipments in 2025. The company was founded as a Harvard spinout in 2021 and is headquartered in Boston, Massachusetts. CytoTronics is commercializing a CMOS-powered drug discovery platform that provides optics-free, single-cell resolution electrical and electrochemical assays. The platform is an integrated single-cell resolution electrochemical-imaging array that produces electrical and image-like readouts from live cells without optics. Its suite of patented technologies was developed over a decade of research at Harvard and licensed exclusively to CytoTronics via Harvard Office of Technology Development. The company aims to target the roughly $20 billion low-throughput cell-based assay market and quickly progress to higher-throughput workflows to make drug-discovery research more precise, automatic, repeatable, and scalable. Seed funding of $9.25M will be used to commercialize research-demonstrated devices and advance platform development. CytoTronics has opened wet-biology and electronics labs at Agility Labs in Boston to continue R&D and further develop its platform.

Total raised

$23M

Funding rounds

2

Latest round

Seed

Latest activity

Sep 2024